Podcasts about circulating

Even a Shamwow thinks this movie is too wet, it's Circulating the Tapes, the MST3K watchalong podcast on The Aewchcast. On this final Halloweenie episode, Aewch would prefer the jacuzzi scene, as he reviews Revenge of the Creature.Watch Revenge of the Creature…on your copy of the DVD! *Cough* righthere! *Cough*The CTT UERL Top Ten!I Accuse MY ParentsGodzilla vs MegalonMaster Ninja 1AvalancheWerewolfThe StarfightersTeenage StranglerSwamp DiamondsPrince of SpaceZombie NightmareSocial Media:@JustAewchEmail: aewch64@gmail.com

This is absolutely fascinating, it's Circulating the Tapes, the MST3K watchalong podcast on the Aewchcast.  On this Halloweenie episode, Aewch wonders if they offer werewolf training, as he reviews Werewolf.Watch Werewolf Right Here!The CTT UERL Top 10!I Accuse My ParentsGodzilla vs MegalonMaster Ninja 1AvalancheThe StarfightersTeenage StranglerSwamp DiamondsPrince of SpaceZombie NightmareSquirmSocial Media:@JustAewchEmail: aewch64@gmail.com

En esta cápsula de ESMO 2025 EXPRESS, el Dr. Mariano Dioca, oncólogo médico adscrito al Instituto de Oncología Ángel H. Roffo en Buenos Aires, Argentina, nos habla sobre las principales novedades en tumores gastrointestinales, destacando cuatro estudiosrelevantes:El estudio PHERFLOT (fase II) evaluó pembrolizumab y trastuzumab en combinación con FLOT frente FLOT en pacientes HER2-positivos con cáncer gástrico o de la unión esofagogástrica. El PERISCOPE II (fase III) analizó la citorreducción peritoneal más HIPEC en cáncer gástrico avanzado, sin demostrar beneficio en supervivencia global.El CITRIC (fase II) exploró el retratamiento con cetuximab + irinotecán frente a terapia estándar (sin inhibidores de EGFR). Finalmente, el PARERE (fase II) comparó las secuencias panitumumab-regorafenib versus regorafenib-panitumumab en el contexto de rechallenge anti-EGFR. 4En conjunto, estos estudios aportan evidencia relevante sobre el papel del rechallenge anti-EGFR y las estrategias inmuno-quimioterápicas en cáncer gástrico y colorrectal avanzado. Referencias:Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive localized esophagogastric adenocarcinoma: Interim analysis of the phase II PHERFLOT/IKF-053 trial of the AIO study group (AIO STO 0321). Abstract # 2095MO, presentado en el marco del Congreso Anual de la Sociedad Europea de Oncología Médica (ESMO®) 2025, celebrado del 17 al 21 de octubre de 2025 en Berlín, Alemania.Systemic therapy, gastrectomy and CRS/HIPEC vs systemic therapy alone for gastric cancer with limited peritoneal dissemination: Results of the randomised PERISCOPE II trial. Abstract #2096MO, presentado en el marco del Congreso Anual de la Sociedad Europea de Oncología Médica (ESMO®) 2025, celebrado del 17 al 21 de octubre de 2025 en Berlín, Alemania.Circulating tumor (ct) DNA-guided anti-EGFR rechallenge strategy in metastatic colorectal cancer (mCRC): Final results of the phase II randomized CITRIC trial. Abstract #LBA33, presentado en el marco del Congreso Anual de la Sociedad Europea de Oncología Médica (ESMO®) 2025, celebrado del 17 al 21 de octubre de 2025 en Berlín, Alemania.Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA (ctDNA): Final results of the randomized PARERE trial by GONO. Abstract #LBA32, presentado en el marco del Congreso Anual de la Sociedad Europea de Oncología Médica (ESMO®) 2025, celebrado del 17 al 21 de octubre de 2025 en Berlín, Alemania.Fecha de grabación: 18 de octubre de 2025 Material exclusivo para profesionales de la salud. Estematerial ha sido desarrollado únicamente con fines educativos e informativos y no tiene la intención de sustituir el juicio clínico de los profesionales de la salud. Las opiniones y declaraciones presentadas en este contenido son responsabilidad exclusiva de los ponentes y no reflejan necesariamente la postura institucional de ScienceLink ni de terceros mencionados. La información presentada se basa en el conocimiento y la experiencia profesional de los ponentes. La veracidad, exactitud y actualidad científica de los datos son de su exclusiva responsabilidad. Así mismo garantizan que el contenido utilizado no infringe derechos de autor de terceros y asumen toda responsabilidad por su uso. Se deberán de revisar las indicaciones aprobadas en el país con estricto apego al marco regulatorio aplicable para cada uno de los tratamientos y medicamentos comentados.  ESMO® es una marca registrada de la European Society ForMedical Oncology. Este material ha sido producido de manera independiente y no está autorizado, patrocinado ni avalado por dicha organización.

The Drive is starting to hear report that Chiefs OC Matt Nagy could be hired by the Tennessee Titans.

A Metaphysician doesn't believe you can podcast when you're dead. It's Circulating the Tapes, the MST3K watchalong podcast on The AewchCast. On this Halloweenie episode, it's like playing an even more boring version of Clue, as Aewch reviews The Dead Talk Back. Plus, the company that makes Budweiser wants to sell you a freezer in The Selling Wizard.Watch The Dead Talk Back Right Here! The CTT UERL Top 10!I Accuse My ParentsGodzilla vs MegalonMaster Ninja 1AvalancheThe StarfightersTeenage StranglerSwamp DiamondsPrince of SpaceZombie NightmareSquirmSocial Media: @JustAewchEmail: aewch64@gmail.com

Patrick Kenny, Commission Member with the CCPC, highlights the Tucson products which are installed in home heating systems that the CCPC have issued an urgent safety alert over.

The only burger joint out of brains, it's Circulating the Tapes, the MST3K watchalong podcast on The Aewchcast. On this first Halloweenie episode, it's a basic zombie movie, but Tia Carrera had to start somewhere, as Aewch reviews Zombie Nightmare.Watch Zombie Nightmare Right Here!The CTT UERL Top Ten!I Accuse My ParentsGodzilla vs MegalonMaster Ninja 1AvalancheThe StarfightersTeenage StranglerSwamp DiamondsPrince of SpaceSquirmThe Million Eyes of SumuruSocial Media: @JustAewchEmail: aewch64@gmail.com

Always wear a helmet in the wasteland, it's Circulating the Tapes, the MST3K watchalong podcast on the Aewchcast. On this episode, Aewch is more of a Fallout guy himself, as he reviews Warrior of the Lost World.Watch Warrior of the Lost World Right Here!The CTT UERL Top Ten!I Accuse My ParentsGodzilla vs MegalonMaster Ninja 1AvalancheThe StarfightersTeenage StranglerSwamp DiamondsPrince of SpaceSquirmThe Million Eyes of SumuruSocial Media:@JustAewchEmail: aewch64@gmail.com

In this episode of Blood Cancer Talks, hosts Eddie, Ashwin, and Raj welcome two distinguished experts to explore the cutting-edge field of circulating tumor DNA (ctDNA) in B-cell lymphomas. Dr. David Russler-Germain, a lymphoma clinician from Siteman Cancer Centre at Washington University in St. Louis, returns as a familiar voice to the podcast audience. Joining him is Dr. Ash Alizadeh, the Moghadam Family Professor of Medicine, Oncology, and Hematology at Stanford University and leader of the Cancer Genomics Program at Stanford Cancer Institute. Dr. Alizadeh has been instrumental in advancing our understanding of lymphomagenesis and lymphoma genetics over the past two decades, pioneering multiple ctDNA techniques that are revolutionizing cancer care. Together, they discuss the transformative potential of ctDNA technology in B-cell lymphomas, particularly DLBCL, covering everything from the technical evolution of biomarker detection to groundbreaking clinical data that may reshape how we monitor and treat these aggressive cancers. Key Discussion Topics1. Genetic Heterogeneity in B-Cell LymphomasComplex genetic landscape of DLBCLImplications for treatment strategiesNeed for personalized approaches 2. Clinical Need for ctDNA in LymphomaWhy ctDNA is needed in aggressive lymphomas:Curative vs. non-curative treatment settingsLimitations of current PET imagingAdditional prognostic information beyond imagingRisk stratification capabilitiesPotential to avoid overtreatmentTherapy adaptation opportunities 3. Challenges in Lymphoma MRD AssessmentWhy lymphoma MRD is more complex than other hematologic malignancies:Differences from acute leukemias, CLL, and myelomaTechnical challenges specific to lymphoid tumorsLower circulating tumor burden compared to liquid tumors 4. ClonoSEQ TechnologyMechanism: Immunoglobulin sequencing approachAdvantages: Established platform with regulatory approvalDisadvantages: Limited sensitivity in peripheral blood, requires adequate tumor sample 5. CAPP-Seq TechnologyFull Name: Cancer Personalized Profiling by Deep SequencingInnovation: Developed ~10 years ago by Dr. Alizadeh's groupMechanism: Targeted sequencing of cancer-specific mutationsAdvantages: High sensitivity, personalized approach 6. PhasED-Seq TechnologyEvolution: Next-generation advancement of CAPP-SeqKey Improvements: Enhanced sensitivity and specificityTechnical Advances: Phased variant detection Clinical Data Highlights1. Remission Assessment by ctDNA in LBCL on 5 prospective studies of frontline anthracycline-based chemo-immunotherapy: https://pubmed.ncbi.nlm.nih.gov/40802906/2. Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from HOVON-902 clinical trial: https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.70003. Korean data on prognostic utility of ctDNA: https://ashpublications.org/blood/article/142/Supplement%201/69/501573 

Where's Scoob and the gang when you need them? It's Circulating the Tapes, the MST3K watchalong podcast on the Aewchcast. On this episode, Aewch doesn't solve the crime, but somehow solves the movie first, as he reviews Teenage Strangler. Plus, the short that drove more people to elope, Is This Love?Watch Teenage Strangler Right Here!The CTT UERL Top Ten!I Accuse My ParentsGodzilla vs Megalon Master Ninja 1AvalancheThe StarFightersSwamp DiamondsPrince of SpaceSquirmThe Million Eyes of SumuruLords of the DeepSocial Media: @JustAewchEmail: aewch64@gmail.com

On this weeks program Chris interviews Sally from Streets Alive Darebin about ongoing issues with risky St George's Road intersections, crossovers and connections.We discuss historial changes, including 2009 change from a roundabout at  Northcote to signalised intersection, working on building a direct connection to Merri Creek Path, Northern Pipe Trail connections to the north, safety issues with crossovers to central median path as it's a major tram route and the premier cycling route in the north of Melbourne with over half a million cycle journeys a year.Streets Alive Darebin are calling on Kat Theophanous: Member for Northcote and Gabrielle Williams: Minister for Transport Infrastructure, Minister for Public and Active Transport and VicRoads to fix the southern intersection at Charles and Merri Parade to improve safety for cyclists, and all road users, connecting to the shared median path heading north.Join Us for Critical Mass St George's Road: meet State Library, 5.30pm Thursday 25 September 2025 (Grand Final Eve) and ride to St George's Road intersection & post ride drinks and chat at Terminus Hotel.Local news: it's World Car Free Day, with today's diminished traffic today it felt like Melburnians had taken that to heart but no, it's the start of Victorian school holidays.After a long wait, Wellington Street north consultation is finally open - Option 1 for a Bicycle Street is the best! Survey is open to Monday 13 October 2025.Circulating back to last fortnights 3CR program, Victoria's new Speed Zoning Policy + Making Moreland Road safer, Victorian Police have made an arrest for the Moreland Road hit-run fatality on 24 August 2025. Please add your name to the Victorian Government Legislative Council petition: Pedestrian and cyclist safety on Moreland Road.Changes to e-bikes: instead of a blanket ban on NSW trains: Commuters taking converted e-bikes on NSW trains, metro to face finesCan you help 3CR by becoming a Regular Donor during September? A Regular Donor is someone who loves 3CR so much that they set up an automatic donation on the same day every month. By becoming a Regular Donor, you can help us stay resilient and radical. Together, we can keep independent voices on air!Program musicTour de Velo, Jon BrennerNew Prophets, Bonobo

On this episode of Nailing the Apex 00:00 The Ferrari rumours 18:46 Baku Sim Lap 18:46 Who has the advantage at Baku? 19:26 Will Issac Hadjar be moving to Red Bull? 28:38 Thoughts on the F1 Movie Learn more about your ad choices. Visit megaphone.fm/adchoices

Technology is Dan's worst enemy yet again as he provides updates on Tyler Robinson | aired on Wednesday, September 17th, 2025 on Nashville's Morning News with Dan Mandis. See omnystudio.com/listener for privacy information.

Time now for our daily Tech and Business Report. Today, Google has announced plans to crackdown on the spread of non-consensual images. For more, KCBS Radio anchor Holly Quan spoke with Bloomberg's Janne Knodler.

Talk about here, fishy fishy, It's Circulating the Tapes, the MST3K watchalong podcast on The Aewchcast. On this episode, Aewch completely forgets who is on the heist crew, as he reviews Killer Fish.Watch Killer Fish….on your own copy of the DVD.The CTT UERL Top Ten!I Accuse My ParentsGodzilla vs Megalon Master Ninja 1AvalancheThe StarFightersSwamp DiamondsPrince of SpaceSquirmThe Million Eyes of SumuruLords of the DeepSocial Media: @JustAewchEmail: aewch64@gmail.com

Steve Gruber discusses news and headlines 

Pass the shuriken on the left hand side, it's Circulating the Tapes, the MST3K Watchalong podcast on The AewchCast. In this episode, Aewch needs a skinnier stunt double as he reviews Master Ninja 1.Watch Master Ninja 1 Right Here!The CTT UERL Top Ten!I Accuse My ParentsGodzilla vs MegalonAvalancheThe StarfightersSwamp DiamondsPrince of SpaceSquirmThe Million Eyes of SumuruLords of the DeepThe Crawling EyeSocial Media: @JustAewchEmail: aewch64@gmail.com

Love the episode? Send us a text!In this special episode of Breast Cancer Conversations, host Laura Carfang speaks with Dr. Troso  about the evolving role of DNA testing in breast cancer care. Together, they break down the three main types of testing:Hereditary genetic testing: Identifying inherited mutations such as BRCA1, BRCA2, and PALB2 (among others) that increase cancer risk and influence prevention and treatment decisions.Somatic (tumor) testing: Analyzing mutations within the tumor itself—such as PIK3CA or ESR1 mutations—to guide targeted therapies and manage resistance in advanced disease.Circulating tumor DNA (ctDNA) testing: Also known as a liquid biopsy, this emerging tool uses blood tests to detect cancer DNA fragments. It holds promise for monitoring recurrence, guiding treatment earlier, and advancing clinical trials.Tune into this Special! 

How can conversation become a real driver of circular transformation? In this episode, George Marshall explains why conversations are central to circular change and how to design them to build trust, reach across difference, and motivate action. Circular economy strategies often focus on systems and structures but lasting change only happens when people connect new behaviors to their own identity and values. Without shared understanding and engagement, technical solutions risk staying at the surface. Recorded live at the LOOP Forum 2025, his keynote explores how businesses can move beyond top-down messaging to create real dialogue that activates people at every level of an organisation. This episode is part of our series on the LOOP Forum 2025 highlights, bringing you the key ideas and insights from this year's leading Nordic event on circularity.

Get born to be mild, because it's Circulating the Tapes, the MST3K watchalong podcast on The AewchCast. On this episode, Aewch tosses around more smack than Maxwell's silver hammer as he reviews The Hellcats.Watch The Hellcats Right Here!The CTT UERL Top Ten!I Accuse My ParentsGodzilla vs MegalonAvalancheThe StarfightersSwamp DiamondsPrince of SpaceSquirmThe Million Eyes of SumuruLords of the DeepThe Crawling EyeSocial Media: @JustAewchEmail: aewch64@gmail.com

All bikini but no A-go-go, it's Circulating the Tapes, the MST3K watchalong podcast on The AewchCast. On this episode, what Aewch wouldn't give to work for a cabal of sexy evil women, as he reviews The Million Eyes of Sumuru.Watch The Million Eyes of Sumuru Right Here!The CTT Ultimate Episode Ranking Top 10!I Accuse My ParentsGodzilla vs MegalonAvalancheThe StarfightersSwamp DiamondsPrince of SpaceSquirmLords of the DeepThe Crawling EyeThe Day Time EndedSocial Media: @JustAewchEmail: aewch64@gmail.com

Don't Touch that Connors, it's Circulating the Tapes, the MST3K watchalong Podcast on The AewchCast. On this episode, Aewch goes red, white, and blonde, as he reviews Swamp Diamonds. Plus, the short that gave the A/V club hope, What to Do on a Date.Watch Swamp Diamonds Right Here!The CTT Top Ten!I Accuse My ParentsGodzilla vs MegalonAvalancheThe StarfightersPrince of SpaceSquirmLords of the DeepThe Crawling EyeThe Day Time EndedTeenage CavemanSocial Media: @JustAewchEmail: aewch64@gmail.com

Put on your best polyester skisuit, it's Circulating the Tapes, the MST3K watchalong podcast on The Aewchcast. On this episode, Aewch swears he can tell the difference between real snow and styrofoam boulders as he reviews Avalanche.Watch Avalanche…on your copy of the DVD.The CTT Ultimate Episode Ranking Top Ten List!I Accuse My ParentsGodzilla vs MegalonThe StarfightersPrince of SpaceSquirmLords of the DeepThe Crawling EyeThe Day Time EndedTeenage CavemanRacket GirlsSocial Media: @JustAewchEmail: aewch64@gmail.com

Follow the Rule and listen to Circulating the Tapes, the MST3K watchalong podcast on The Aewchcast. On this episode, Aewch dares to enter the forbidden zone, as he reviews Teenage Caveman. Plus, TWO shorts, the nightmare of safety known as Aquatic Wizards, and the scourge to animals Catching Trouble.Watch Teenage Caveman Right Here!The CTT Ultimate Episode Ranking List!I Accuse My ParentsGodzilla vs MegalonThe StarfightersPrince of SpaceSquirmLords of the DeepThe Crawling EyeThe Day Time EndedRacket GirlsSocial Media: @JustAewchEmail: aewch64@gmail.com

Get your hands on some spiritual Gak, because it's Circulating the Tapes, the MST3K watchalong podcast on The Aewchcast. On this episode, Aewch borrows a mini-sub(Don't worry, there's plenty left), as he reviews Lords of the Deep.Watch Lords of the Deep…on your copy of the DVD.The CTT Ultimate Episode Ranking List!I Accuse My ParentsGodzilla vs MegalonThe StarfightersPrince of SpaceSquirmThe Crawling EyeThe Day Time EndedRacket GirlsSocial Media: @JustAewchEmail: aewch64@gmail.com

BUFFALO, NY – July 24, 2025 – A new #casereport was #published in Volume 16 of Oncotarget on July 23, 2025, titled “Extracorporeal blood filtration leading to tumor growth arrest and reduced analgesic requirements in Stage IV poorly differentiated pancreatic adenocarcinoma: A case report.” In this report, Susanna Ulahannan from the University of Oklahoma Health Sciences Center and colleagues describe the use of extracorporeal blood filtration in a patient with metastatic pancreatic cancer. The patient experienced clinical improvement, reduced pain, and no signs of new tumor growth over 12 months of follow-up. Metastatic pancreatic cancer is difficult to treat and is often diagnosed at an advanced stage. In this case, a 51-year-old woman with stage IV poorly differentiated adenocarcinoma chose not to undergo standard chemotherapy. Instead, she received extracorporeal blood filtration with the Seraph® 100 device, which is designed to remove circulating tumor cells (CTCs) from the bloodstream. CTCs are thought to contribute to the spread of cancer to other organs. “Circulating tumor cells (CTC's) are tumor cells that are shed from the primary tumor and travel via blood or lymphatic system to form micro metastases in distant organs under a suitable environment.“ The patient received between nine and twelve treatments over the course of a year. These treatments were performed both abroad, where the device is approved for this use, and under a clinical protocol in the United States. Medical imaging showed that her disease remained stable, with no new metastases detected. She also reported improvements in appetite, energy levels, and pain control. Her opioid use was reduced by 90%. Blood samples confirmed a drop in CTC levels after treatment. This observation supports the idea that removing CTCs might help limit cancer progression in some patients. However, given that this is a single case report, larger clinical studies are needed to evaluate the effectiveness of this approach. The mechanism behind the patient's pain relief is not fully understood. Authors suggest that it may be related to the reduction of tumor cells or inflammatory molecules in the blood. Researchers noted that pro-inflammatory cytokines, known to influence pain, could also have been affected by the filtration process. This is the first documented case of stable disease and reduced symptoms following CTC filtration in advanced pancreatic cancer. While these findings should not be generalized, they highlight an approach outside standard protocols that should be further explored in clinical research. Future studies will be needed to determine whether this method can contribute to symptom management or disease control in other patients with metastatic pancreatic cancer. DOI - https://doi.org/10.18632/oncotarget.28756 Correspondence to - Susanna Ulahannan - susanna-ulahannan@ouhsc.edu Video short - https://www.youtube.com/watch?v=dro6iUGDrVQ Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28756 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, extracorporeal blood filtration, circulating tumor cells, metastatic pancreatic cancer, seraph 100, OncoBind To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

I'm…getting a…vision…A Podcast called Circulating the Tapes, the MST3K watchalong podcast on The Aewchcast. On this episode, Aewch does a deep dive into some Best Brains history, as he reviews the first episode of MST3K (Sans KTMA), The Crawling Eye. Watch The Crawling Eye Right Here!The CTT Ultimate Episode Ranking List!I Accuse My ParentsGodzilla vs MegalonThe StarfightersPrince of SpaceSquirmThe Day Time EndedRacket GirlsSocial Media: @JustAewchEmail: aewch64@gmail.com

Jeff Grubb is joined by Kat Bailey to start the week. We chat about a banana boatload of Donkey Kong Bananza related stories, the price of the Asus ROG Ally Xbox device getting leaked, EA shelving the Need for Speed franchise, and more stories for your Monday morning!

Get your monster goofin' going, because this is Circulating the Tapes, the MST3K watchalong Podcast on The Aewchcast. On this episode, Aewch embodies the spirit of bad movies as he reviews Godzilla vs. Megalon.Watch Godzilla vs Megalon Right Here!The CTT Ultimate Episode Ranking List!I Accuse My ParentsThe StarfightersPrince of SpaceSquirmThe Day Time EndedRacket GirlsSocial Media: @JustAewchEmail: aewch64@gmail.com

(SPOILER) Your Daily Roundup covers Big Brother 27 premiering tonight, the rumor mill already starting about one contestant, Jesse from the Valley on a podcast giving his thoughts on Janet, and a new raw dogging challenge on a flight that is more up my alley.       Music written by Jimmer Podrasky (B'Jingo Songs/Machia Music/Bug Music BMI) Ads: ZocDoc – Click on https://zocdoc.com/RealitySteve to find and instantly book a top rated doctor today.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Is that a Weird green Mayan pyramid in your pocket, or are you happy to see me? Because this is Circulating the Tapes, the MST3K watchalong podcast on The Aewchcast. On this episode, Aewch tries to keep up, but falls off the edge of the universe, as he reviews The Day Time Ended.Watch The Day Time Ended….on your own copy of the dvd.The CTT Ultimate Episode Ranking List!I Accuse My ParentsThe StarfightersPrince of SpaceSquirmRacket GirlsSocial Media: @JustAewchEmail: aewch64@gmail.com

You da worm face now! Because this is Circulating the Tapes, the MST3K watchalong podcast on The Aewchcast. On this episode, Aewch wonders if you would listen to his podcast if it was a worm podcast, as he reviews Squirm. Plus, the bonus short, A Case of Spring Fever.Watch Squirm Right Here!The CTT Ultimate Episode Ranking List!I Accuse My ParentsThe StarfightersPrince of SpaceRacket GirlsSocial Media: @JustAewchEmail: aewch64@gmail.com

Your weapons have no effect on Circulating the Tapes, the MST3K watchalong podcast on The Aewchcast. On this episode, Aewch likes bootblacking very much, as he reviews Prince of Space.Watch Prince of Space Right Here!Or watch our next episode: Squirm!The Circulating the Tapes Ultimate Episode Ranking List:1: I Accuse My Parents2:The Starfighters3. Racket GirlsSocial Media: @JustAewch

Get your corn detassled, it's Circulating the Tapes, the MST3K Watchalong Podcast on The AewchCast. On this episode, Aewch attempts to find his need for speed, but gets a lot of jet refueling, as he reviews The Starfighters.Watch The Starfighters Right Here!Social Media: @JustAewchEmail: aewch64@gmail.comNext Episode: Prince of Space!

Samira, a breast cancer survivor and CEO of Manta Cares, discusses the latest advancements in cancer treatment with Dr. Doug Blayney at the ASCO conference. They explore the significant impact of exercise on cancer treatment tolerance and survival, the de-escalation of chemotherapy, the introduction of new therapies like SERDs and antibody drug conjugates, and the role of circulating tumor DNA in monitoring cancer recurrence. The conversation emphasizes the importance of patient convenience and self-advocacy in cancer care.About Our Guest:Douglas W. Blayney, MD is a Professor of Medicine (Oncology), Emeritus, former Medical Director of Stanford Cancer Center, and specializes in the treatment of breast cancer. He has a special interest in the quality and value of cancer care. Dr. Blayney is a past president of the American Society of Clinical Oncology (ASCO), a founder of the ASCO Quality Symposium, a co-author of the ASCO value framework descriptions, and instigated the ASCO clinical "big data" effort, which is now CancerLinQ. He received the inaugural Ellen Stovall Award for Leadership in Patient Centered Care from the National Coalition for Cancer Survivorship in 2016. He was previously a Professor of Internal Medicine and Medical Director of the Comprehensive Cancer Center at the University of Michigan, and prior to that practiced and led Wilshire Oncology Medical Group, Inc. a physician owned multidisciplinary oncology practice in southern California. He has expertise on clinical trial development, use of oncology drugs in clinical practice, reimbursement and marketing strategies and information technology use.Chapter Codes00:00 The Impact of Exercise on Cancer Treatment02:00 Interview at ASCO Starts06:00 Advancements in Cancer Treatment: De-escalation and AI11:52 Emerging Therapies: SERDs and Antibody Drug Conjugates18:11 Circulating Tumor DNA: A New Frontier in Monitoring24:01 Convenience in Cancer Care: A Patient-Centric ApproachTakeaways- Regular exercise can increase tolerance to cancer treatments.- Data shows exercise has tangible benefits on survival rates.- De-escalation of chemotherapy is a key focus in cancer treatment.- AI is being integrated into cancer treatment guidelines.- Patients can take proactive steps to improve their health.- Oral SIRDs are emerging as a more convenient treatment option.- Antibody drug conjugates target cancer cells with fewer side effects.- Circulating tumor DNA can help detect cancer recurrence earlier.- Convenience in treatment is becoming a priority for patients.- Competition among treatments may help reduce costs for patients.Tags & Keywords:cancer treatment, ASCO, exercise, AI, SIRDs, antibody drug conjugates, circulating tumor DNA, patient care, chemotherapy, cancer survival, health technologyConnect with Us:Enjoyed this episode? Make sure to subscribe, rate, and review! Follow us on Instagram, Facebook, or Linkedin @mantacares and visit our website at mantacares.com for more episodes and updates.Listen Elsewhere: Website: https://mantacares.com/pages/podcast?srsltid=AfmBOopEP5GJ-Wd2nL-HYAInrwerIVhyJw67salKT-r9Qb_gadBvbHie YouTube: https://youtu.be/UjsAtpbedA8 Spotify: https://open.spotify.com/episode/7HwhjXHZU0ZWWVkXrCSV7V?si=d5e986f0885a4bbb Apple: https://podcasts.apple.com/us/podcast/cervical-cancer-and-hpv-what-you-need-to-know/id1622669098?i=1000710235401 Disclaimer:All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Get your essays ready for the contest, It's Circulating The Tapes, the Mystery Science Theater 3000 Watchalong Podcast on The AewchCast. On this episode, Aewch runs some packages and gets the carrots on ice, as he reviews I Accuse My Parents, with the short The Truck Farmer.Watch I Accuse My Parents Right Here!Listen to our episode on Racket Girls Right Here!Social Media: @JustAewch

In the first episode of a special daily series during the 2025 ASCO Annual Meeting, Dr. John Sweetenham discusses the results of 2 studies on the treatment of advanced colorectal cancer plus an additional study exploring the association of Medicaid expansion with cancer survival outcomes. Transcript Dr. John Sweetenham: Hello, and welcome to our special coverage of the 2025 ASCO Annual Meeting on the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'll be bringing you brief analysis on selected abstracts from each day of the Meeting. My disclosures are available in the transcript of this episode.  Today, I'll be reviewing three abstracts, the first two of which address the treatment of advanced colorectal cancer. Today's first study is Abstract 3501. These data were presented by Dr. Heinz-Josef Lenz from the USC Norris Comprehensive Cancer Center and report on the expanded analysis of the CheckMate-8HW trial. This was a phase 3, international, multicenter trial in patients with MSI-high/MMR-deficient metastatic colorectal cancer, who were randomized between nivolumab (nivo) alone, nivolumab plus ipilumomab (ipi) or investigators' choice of chemotherapy (FOLFOX or FOLFIRI) with or without bevacizumab or cetuximab. The study showed that nivo plus ipi demonstrated superior progression-free survival compared with chemotherapy in the first-line setting and superior progression-free survival compared with nivo alone across all lines of therapy. These results led to the approval of nivo + ipi in the first-line setting in patients with MSI-H/dMMR mCRC in the U.S., the EU, and many other countries.  In today's presentation, Dr. Lenz reported on the expanded analyses of nivo plus ipi versus nivo across all lines of therapy and longer follow-up results for nivo and ipi versus chemo in the first-line setting. With longer follow up (the median is now at 47 months) nivo and ipi continued to show progression-free survival benefit compared with chemotherapy with a median PFS of 54.1 months versus 5.9 months, for a hazard ratio of 0.21.  Additionally, the analysis of the effects on PFS2, defined as the time from randomization to progression after subsequent systemic therapy, start of second subsequent systemic therapy, or death, showed that compared with chemotherapy, first-line nivo and ipi was associated with a 72% reduction in the risk of death or disease progression, despite the fact that 71% of those who progressed following chemotherapy crossed over to receive subsequent immunotherapy. The study also showed that across all lines, nivo and ipi demonstrated superior progression-free survival compared with nivo alone, the median not reached versus 39.3 months, for a hazard ratio of 0.62. No new toxicity signals emerged after further analysis. Most treatment-related adverse events with possible immune etiology were observed within the first six months of therapy. The results for PFS2 are particularly significant. Up to now, there has been some reluctance to use nivo and ipi as first-line therapy, partly because of its toxicity profile and based on the rationale that it would be active after other frontline therapies. The observation in this study that the beneficial effects of nivo and ipi are maintained downstream is compelling. The results suggest that delaying the use of this combination to the second line or later may compromise subsequent PFS and supports the use of nivo and ipi as a standard-of-care frontline option for MSI-H/dMMR metastatic colorectal cancer. Moving on, the next study I'm featuring today is Abstract 3503, presented by Dr. Jeanne Tie from the Peter MacCallum Cancer Centre and the Walter and Eliza Hall Medical Institute of Medical Research from Melbourne, Australia. This study reported the impact of circulating tumor DNA (ctDNA)-guided adjuvant chemotherapy escalation in stage III colon cancer, focused on the primary analysis of the ctDNA-positive cohort from the randomized DYNAMIC-III trial. As background, about 30% of patients with stage III colon cancer will recur following standard-of-care adjuvant therapy with oxaliplatin-based regimens. And current data show that for those patients with high-risk disease, 6 months of chemotherapy is associated with a lower recurrence rate than 3 months. Circulating tumor DNA following initial surgery has been shown to be a strong independent prognostic factor for these patients, but questions remain about how ctDNA can be used for adaptation of treatment. Questions regarding treatment adaptation were addressed in the DYNAMIC-III trials – specifically, does treatment escalation benefit those who are ctDNA positive following surgery, and can therapy be de-escalated for those who are ctDNA negative. The first of these 2 questions – treatment escalation in the positive group – is the subject of this report. One thousand and two patients were randomized in this study, between ctDNA-informed therapy (502) or standard management (500). Of those patients included in the intent to treat cohorts, 129 were ctDNA positive in the ctDNA-informed arm compared with 130 in the standard management arm. Various pre-planned treatment escalation protocols were used, depending on the choice of first-line therapy. With a median follow up of 42.2 months, there was no difference in 3-year relapse free survival between the ctDNA informed group (48%) and the standard management group (52%). There was, however, a highly significant difference in relapse-free survival for patients who cleared ctDNA by the end of treatment compared with those who didn't. The authors concluded that the recurrence risk for this group remains high, at about 50%, after adjuvant therapy and that it increases with higher ctDNA burden, but treatment escalation didn't appear to reduce the recurrence risk. Clearance of ctDNA was associated with a favorable outcome, suggesting that as more effective treatments are developed in the future for this group, ctDNA will likely prove to have major utility. Changing gears now, my final selection for today is Abstract 11006, presented by Dr. Elizabeth Shafer from the American Cancer Society. This study explored the association of Medicaid expansion with 5-year survival after a cancer diagnosis.  Dr. Schafer began her presentation by providing some historical perspective on the impact of the Affordable Care Act on reducing the number of uninsured adults aged less than 65 years in the United States. She then reviewed some recent data on the impact of Medicaid expansion on cancer care, including improved screening rates, improved access to cancer surgery, and an increase in earlier cancer diagnosis. The current study builds on earlier data from the American Cancer Society which showed improved 2-year overall survival for patients with newly diagnosed cancer following Medicaid expansion. The new study reported by Dr. Schafer examined 5-year cause-specific survival in individuals with cancer since Medicaid expansion, analyzed according to cancer type and various demographic and social factors. Using data from more than 813,000 individuals from 26 states that expanded Medicaid compared with more than 610,000 from 12 states that did not, the authors reported that similar improvements in 5-year cause-specific survival were observed in the expansion and the non-expansion states, but when analyzed by other factors, differences in outcome emerged. For example, although similar improvements in survival between expansion and non-expansion states were seen in urban communities, there was a significant improvement of 2.55 percentage points in survival for individuals in rural communities in expansion states compared with those in non-expansion states. Similar trends were observed in high poverty areas, where improvements in survival were superior in expansion versus non-expansion states.  When examined by cancer type, the authors observed greater improvements in 5-year survival for those with pancreatic, lung, and colorectal cancer, possibly due to improvements in screening and early access to treatment.  The authors concluded that those residing in rural and high-poverty areas experienced the most improvement in cause-specific cancer survival following Medicaid expansion. In summary, it's encouraging to see an improving trend in cancer mortality overall, independent of Medicaid expansion, but it's also important to remember that this is yet another study which confirms how implementation of the ACA has improved cancer outcomes and begun to address some of the disparities in cancer care. Join me again tomorrow to hear more top takeaways from ASCO25. And if you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.   Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.     Find out more about today's speaker:  Dr. John Sweetenham    Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn        Disclosures:  Dr. John Sweetenham:  No relationships to disclose 

Featuring a slide presentation and related discussion from Dr John P Leonard, including the following topics: Five-year analysis of the POLARIX trial of polatuzumab vedotin with R-CHP for previously untreated diffuse large B-cell lymphoma (0:00) Epcoritamab, glofitamab and other bispecific antibodies for large B-cell lymphoma (5:33) Circulating tumor DNA as an early outcome predictor in patients with large B-cell lymphoma receiving second-line lisocabtagene maraleucel in the TRANSFORM study (16:44) The bispecific antibodies mosunetuzumab and odronextamab as initial therapy for follicular lymphoma (FL) (19:27) The Phase III inMIND trial of tafasitamab in combination with lenalidomide/rituximab for recurrent FL (22:58) Updated results from studies of bispecific antibodies and chimeric antigen receptor T-cell therapy for relapsed/refractory FL (24:58) Updates from the Phase III TRIANGLE and ECOG-ACRIN EA4151 trials on the role of autologous stem cell transplant in the treatment of previously untreated mantle cell lymphoma (MCL) (27:48) Novel treatment approaches with Bruton tyrosine kinase inhibitors for patients with newly diagnosed MCL (30:53) CME information and select publications

"The biggest mistake is a mindset of scarcity—the fear that there's never enough. The solution is to begin circulating money. Even small acts matter." – Tom LeNoble

Look for the show notes at AnokaCountyHistory.org

Thank God It's Tuesday! We are having a zen day at Spa Mirbeau, hanging out from the Aqua Terrace after a glow facial and plenty of time bouncing from sauna to steam room to shower. We catch up on Intern Aaron's college-y weekend, the latest in documentary TV and play a good old game of Roast or Toast.The Buttonista Show is presented by Michelob Ultra

Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Learn more about your ad choices. Visit podcastchoices.com/adchoices

There have been reported sightings of ICE agents across the North State on social media. But local organizations and law enforcement agencies report most are likely false alarms. Also, Chico State President Steve Perez sent a message to the campus community last week in response to worries about the school's fiscal situation amid a freeze on federal funding, and the second manual snow survey of the season measured 22 inches of snow depth, only 46 percent of average for the location near Echo Summit.

Join our NEW Community Discord! https://www.discord.gg/podcast Today's topics we cover Epic's unforeseen job at handling cheaters. Topics: 1. Clix has his trio snake him in the final week! 2. Will the next LAN be in Raleigh or France? 3. Will Fortnite Competitive officially support the a new game mode? 4. Tune into the Comp awards! https://x.com/CompAwardsFN Follow Us On Twitter: MonsterDface - @MonsterDface Somebodysgun - @Somebodysgun LifeWithPanda - @LifewPanda  Email all of your complaints to us on twitter. Don't forget to leave us a comment!

This week on The Book Drop, we take a deeper look at the top circulating titles of 2024 for OPL, and discuss what they reveal about our community's awesome reading habits. This is The Book Drop.All the books and resources we talk about in this episode can be found at omahalibrary.org/podcast and here. Happening at the Library: Oregon Trail Live Action | Saturday, Jan. 18 | 1 to 3 p.m. | Saddlebrook Branch and Thursday, Jan. 23 | 6 to 7p.m. | Millard Branch Container Gardening Workshop | Tuesday, Jan. 21 | 10:30 to 11:30 a.m. | Swanson Branch Writer's Workshop | Tuesday, Jan. 21 | 5:30 to 7:30 p.m. | Benson Branch Explore all upcoming events at omahalibrary.org/events.